TY - JOUR
T1 - Anti-CD4 monoclonal antibody therapy suppresses autoimmune disease in MRL/Mp-lpr/lpr mice
AU - Jabs, Douglas A.
AU - Burek, C. Lynne
AU - Hu, Qile
AU - Kuppers, Rudolf C.
AU - Lee, Bella
AU - Prendergast, Robert A.
N1 - Funding Information:
’ This study was supported in part by Grants EY05912, EY03521, EY01765, and AR31632 National Institutes of Health, Bethesda, Maryland, and an unrestricted grant from Research Blindness. Dr. Jabs is a Research to Prevent Blindness Olga Keith Wiess Scholar. 2 To whom correspondence should be addressed at The Wilmer Ophthalmological Broadway, Suite 700, Baltimore, MD 2 1205.
PY - 1992/5
Y1 - 1992/5
N2 - MRL/Mp-lpr/lpr (MRL/lpr) mice spontaneously develop systemic autoimmune disease, characterized by vasculitis, lymphadenopathy, glomerulonephritis, and autoantibody formation. The target organ inflammatory lesions are composed largely of CD4+ "helper" T cells, while the massively enlarged lymph nodes are composed primarily of CD3+ CD4- CD8- TCR α β+ "double-negative" T cells. In this study we investigated the effect of treatment of MRL/lpr mice with antiCD4 monoclonal antibody (mAb); control groups consisted of animals treated with normal saline or rat immunoglobulin (Ig). Anti-CD4 mAb treatment, which was started at 4 weeks and continued through 20 weeks of age, resulted in a dramatic reduction of both the frequency and severity of the autoimmune disease, as demonstrated histologically and serologically. Anti-CD4 mAb therapy markedly reduced the frequency of glomerulonephritis and eliminated vasculitis of the major renal arterial branches. Glomerulonephritis was detected in 9 of 9 saline-treated, 9 of 9 rat Igtreated, but in only 1 of 9 anti-CD4 mAb-treated mice; vasculitis was detected in 6 of 9 salinetreated, 7 of 9 rat Ig-treated, but in none of 9 anti-CD4 mAb-treated mice. The frequency of antinuclear antibodies, titer of anti-dsDNA antibodies, and total Ig levels were all significantly reduced by anti-CD4 mAb therapy. These data support the hypothesis that CD4+ T cells play a central role in the disease process in this autoimmune strain.
AB - MRL/Mp-lpr/lpr (MRL/lpr) mice spontaneously develop systemic autoimmune disease, characterized by vasculitis, lymphadenopathy, glomerulonephritis, and autoantibody formation. The target organ inflammatory lesions are composed largely of CD4+ "helper" T cells, while the massively enlarged lymph nodes are composed primarily of CD3+ CD4- CD8- TCR α β+ "double-negative" T cells. In this study we investigated the effect of treatment of MRL/lpr mice with antiCD4 monoclonal antibody (mAb); control groups consisted of animals treated with normal saline or rat immunoglobulin (Ig). Anti-CD4 mAb treatment, which was started at 4 weeks and continued through 20 weeks of age, resulted in a dramatic reduction of both the frequency and severity of the autoimmune disease, as demonstrated histologically and serologically. Anti-CD4 mAb therapy markedly reduced the frequency of glomerulonephritis and eliminated vasculitis of the major renal arterial branches. Glomerulonephritis was detected in 9 of 9 saline-treated, 9 of 9 rat Igtreated, but in only 1 of 9 anti-CD4 mAb-treated mice; vasculitis was detected in 6 of 9 salinetreated, 7 of 9 rat Ig-treated, but in none of 9 anti-CD4 mAb-treated mice. The frequency of antinuclear antibodies, titer of anti-dsDNA antibodies, and total Ig levels were all significantly reduced by anti-CD4 mAb therapy. These data support the hypothesis that CD4+ T cells play a central role in the disease process in this autoimmune strain.
UR - http://www.scopus.com/inward/record.url?scp=0026637355&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0026637355&partnerID=8YFLogxK
U2 - 10.1016/0008-8749(92)90166-M
DO - 10.1016/0008-8749(92)90166-M
M3 - Article
C2 - 1576659
AN - SCOPUS:0026637355
SN - 0008-8749
VL - 141
SP - 496
EP - 507
JO - Cellular Immunology
JF - Cellular Immunology
IS - 2
ER -